最新消息

Australia: TGA released guidance to clarify the regulatory obligations of sponsors and manufacturers with exempt medical devices - August/September 2024

Australia: TGA released guidance to clarify the regulatory obligations of sponsors and manufacturers with exempt medical devices - August/September 2024

  • 2024-09-17 06:17:58

Australia's TGA has issued new guidelines for exempt medical devices, clarifying that while not requiring ARTG registration, these products still face strict oversight. Manufacturers must adhere to reporting, recall, advertising, and quality standards to ensure patient safety. Non-compliance can result in penalties.

了解更多
QT ANALYSIS: OVERVIEW OF NEW AND IMPACTING GLOBAL REGULATORY UPDATE FOR 2024  - DECEMBER/JANUARY 2024

QT ANALYSIS: OVERVIEW OF NEW AND IMPACTING GLOBAL REGULATORY UPDATE FOR 2024 - DECEMBER/JANUARY 2024

  • 2023-12-28 09:01:53

In this latest edition, we navigate the evolving landscape of medical device regulations, marked by progress and heightened vigilance. The improvement of technology and healthcare is making things better for patients, but it also needs careful supervision. Over the past year, global regulatory bodies have demonstrated adaptability, reinforcing frameworks to manage medical device registrations effectively.

This edition offers a concise analysis of the latest mandates, impending updates, and pivotal shifts for 2024, addressing the exchange between technological innovation and the mission to ensure global safety and efficacy.

了解更多
SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

  • 2023-07-21 02:32:25

Singapore's Health Science Authority (HSA) is pleased to announce their status as a recognized Stringent Regulatory Authority (SRA) for Class C and D IVD by WHO. The SRA status means high-risk IVD products registered with HSA might obtain faster evaluation through WHO prequalification assessment, enabling manufacturers accelerated access to global markets.

了解更多